GleamWall
中文EN

MIRA MIRA PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1904286

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY100.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-135.7%
ROA-131.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio16.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-66.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$1.72M$3.31M
SG&A expense$8.77M$4.71M
Interest expense—-$165,669
Net income-$10.44M-$7.85M
EPS (basic)-1.35-0.51
EPS (diluted)-1.35-0.51
Weighted avg. shares (diluted)—15.44M
Banking
Net interest income$98,911$165,669
Balance sheet
Cash & equivalents$6.35M$2.83M
Short-term investments$4.68M—
Current assets$11.06M$2.89M
Total assets$11.09M$2.92M
Current liabilities$702,068$723,349
Total liabilities$702,068$723,349
Shareholders' equity$10.39M$2.20M
Shares outstanding41.94M16.56M
Cash flow statement
Operating cash flow-$4.66M-$5.56M
Financing cash flow$8.18M$3.79M
Stock-based compensation$6.31M$1.92M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.